We are thrilled to attend the 10th Annual Stanford Drug Discovery Symposium from April 27th - 28th, 2026. Let’s come together to celebrate this special milestone year with a packed program featuring two days of engaging discussions and poster sessions on innovative research findings. Connect with our Biocytogen team to learn how we can enhance and accelerate your drug discovery journey.
What is the 10th Annual Stanford Drug Discovery Symposium?
The Stanford Drug Discovery Symposium is an annual forum focused on encouraging interdisciplinary collaborations to drive drug research and improve patient care. This is a great opportunity for researchers, industry professionals, and key stakeholders interested in networking and learning about the future outlook of drug discovery.
Event Overview
Date: April 27th - 28th, 2026
Venue: Frances C. Arrillaga Alumni Center, 326 Galvez St, Stanford, CA 94305
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s shape the future of drug discovery together, we look forward to meeting you in Stanford, CA!
